Shots:
- OXB to receive $4.83M as an option exercise fee & ~$37.96M in development, regulatory & sales milestones along with royalty on sales of a CF gene therapy product under an option & license agreement with Boehringer Ingelheim as reported in Aug’18
- Boehringer Ingelheim has also exercised its option to license IP from IP & UK Cystic Fibrosis Gene Therapy Consortium of lentiviral vector-based product for CF
- The collaboration focuses on the development of a lentiviral vector in an inhaled formulation to introduce a CFTR gene into the relevant target cell. OXB expects to produce large quantities of lentiviral vectors using a GMP-compliant manufacturing process in bioreactors
Click here to read the full press release/ article | Ref: Globe Newswire | Image: Franchise India
The post Boehringer Ingelheim Exercised its Option to License Oxford Biomedica’s Lentiviral Vector Technology to Commercialize BI 3720931 for CF first appeared on PharmaShots.
